Published in Evid Based Med on February 18, 2012
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol (2011) 1.59
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J (2013) 1.43
Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation (2010) 1.31
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26
Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunction. Circ Cardiovasc Qual Outcomes (2011) 1.24
Retrograde ascending aortic dissection as an early complication of thoracic endovascular aortic repair. J Vasc Surg (2012) 1.22
Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. J Cardiovasc Electrophysiol (2009) 1.19
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Cerebral magnetic resonance findings in asymptomatic patients after atrial fibrillation catheter ablation: cause for alarm or further study? J Cardiovasc Electrophysiol (2011) 1.06
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol (2013) 1.02
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes (2013) 0.97
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA (2013) 0.96
Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc (2013) 0.94
Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. Am Heart J (2009) 0.93
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Ther (2010) 0.91
Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). JACC Heart Fail (2013) 0.91
Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. Pacing Clin Electrophysiol (2013) 0.89
The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. Circ Cardiovasc Genet (2011) 0.89
Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. Europace (2011) 0.87
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J (2012) 0.86
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med (2013) 0.86
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86
Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. Am J Ther (2010) 0.84
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes (2013) 0.83
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? Europace (2011) 0.83
Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. Circulation (2016) 0.82
Intraoperative Magnesium Administration Does Not Reduce Postoperative Atrial Fibrillation After Cardiac Surgery. Anesth Analg (2015) 0.82
Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. Ann Intern Med (2014) 0.82
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Localization of pacing and defibrillator leads using standard x-ray views is frequently inaccurate and is not reproducible. J Interv Card Electrophysiol (2015) 0.81
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc (2013) 0.81
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J (2012) 0.81
Cardiac conduction system disease after transcatheter aortic valve replacement. Am Heart J (2012) 0.81
International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J (2012) 0.81
Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics (Sao Paulo) (2011) 0.80
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J (2013) 0.79
Preprocedural ECG-gated computed tomography for prevention of complications during lead extraction. Pacing Clin Electrophysiol (2014) 0.79
Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin Cardiol (2013) 0.79
Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol (2011) 0.78
Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. Expert Rev Cardiovasc Ther (2015) 0.77
Completion of guideline-recommended initial evaluation of atrial fibrillation. Clin Cardiol (2012) 0.77
Prognostic validation of an algorithm to convert myocardial perfusion SPECT imaging data from a 12-segment model to a 17-segment model. J Nucl Cardiol (2009) 0.77
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis (2008) 0.77
Left atrial remodeling: shape before size? J Cardiovasc Electrophysiol (2013) 0.75
Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on. J Cardiovasc Electrophysiol (2014) 0.75
Putting risk prediction in atrial fibrillation into perspective. Eur Heart J (2012) 0.75
Atrial fibrillation and stroke: it's not necessarily all about the rhythm. Heart Rhythm (2011) 0.75
ECG interpretation in ST-elevation myocardial infarction: pattern recognition or caliper measurements? Heart (2008) 0.75
Risk assessment in atrial fibrillation: not all factors are created equal. Europace (2013) 0.75
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. Circulation (2013) 0.75
Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure. Heart Fail Clin (2013) 0.75
Validation of non-contact and point-to-point mapping in a single electroanatomic map. Europace (2013) 0.75
Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. J Cardiovasc Electrophysiol (2014) 0.75
Mandatory diagnostic screening tests to individualize therapy: a curious paradox. Circ Arrhythm Electrophysiol (2012) 0.75
Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. Am Heart J (2011) 0.75
Cardiac implantable electronic device removal in patients with left ventricular assist device associated infections. J Cardiovasc Electrophysiol (2014) 0.75
Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. Heart Fail Rev (2011) 0.75
The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. Heart Fail Clin (2013) 0.75
Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? J Thromb Thrombolysis (2016) 0.75
Highlights from American Heart Association, November 4-7, 2007, Orlando, Florida, USA. Late-breaking trials summary. Am Heart J (2008) 0.75